Table 3.
National policy recommendations for HCV screening during pregnancy, testing and treating children and/or adolescents, among countries with an NSP and/or guidelines.
| National policies in number (%) of countries |
|||||||
|---|---|---|---|---|---|---|---|
| Screen all pregnant women | Screen some pregnant women | Screen children born to mothers with HCV | Test other children and/or adolescents for HCV | Treat children and/or adolescents for HCV∗ | ’Treat all’ but no policy specified for children | ||
| Total n = 122 | 19 (16%) | 13 (11%) | 42 (34%) | 5 (4%) | 33 (27%) | 20 (16%) | |
| By WHO region | |||||||
| African n = 20 | 3 (15%) | 1 (5%) | 1 (5%) | 0 | 0 | 0 | |
| Eastern Mediterranean n = 10 | 3 (30%) | 0 | 5 (50%) | 0 | 3 (30%) | 2 (20%) | |
| European n = 44 | 8 (18%) | 8 (18%) | 18 (41%) | 2 (45%) | 17 (39%) | 10 (23%) | |
| Americas n = 22 | 3 (14%) | 2 (9%) | 5 (23%) | 0 | 5 (23%) | 5 (23%) | |
| South-East Asia n = 11 | 1 (9%) | 1 (9%) | 7 (64%) | 1 (9%) | 2 (18%) | 2 (18%) | |
| Western Pacific n = 15 | 1 (7%) | 1 (7%) | 6 (40%) | 2 (13%) | 6 (40%) | 1 (7%) | |
| By income classification | |||||||
| High-income n = 46 | 4 (9%) | 9 (20%) | 17 (37%) | 0 | 13 (28%) | 12 (26%) | |
| Upper middle-income n = 32 | 6 (19%) | 2 (6%) | 11 (34%) | 2 (6%) | 10 (31%) | 7 (22%) | |
| Lower middle-income n = 27 | 7 (26%) | 1 (4%) | 13 (48%) | 2 (7%) | 9 (33%) | 1 (4%) | |
| Low-income n = 17 | 2 (12%) | 1 (6%) | 1 (6%) | 1 (6%) | 1 (6%) | 0 | |
| N/A | 0 | 0 | 0 | 0 | 0 | 0 | |
NSP, national strategic plan.
∗
Details of treatment regimens are shown in Table 5.